(NYSE: TAK) Takeda Pharmaceutical Co's forecast annual revenue growth rate of -1.16% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.14%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Takeda Pharmaceutical Co's revenue in 2025 is $32,106,173,791.On average, 1 Wall Street analysts forecast TAK's revenue for 2026 to be $45,998,534,504,410, with the lowest TAK revenue forecast at $45,998,534,504,410, and the highest TAK revenue forecast at $45,998,534,504,410. On average, 2 Wall Street analysts forecast TAK's revenue for 2027 to be $47,021,973,288,183, with the lowest TAK revenue forecast at $45,657,257,105,682, and the highest TAK revenue forecast at $48,386,689,470,683.
In 2028, TAK is forecast to generate $48,786,789,893,179 in revenue, with the lowest revenue forecast at $48,786,789,893,179 and the highest revenue forecast at $48,786,789,893,179.